Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
8 search results for:

SABCS 2022 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 06-12-2022 | SABCS 2022 | Conference coverage | Channel

    SABCS 2022

    News and expert insight from the 2022 San Antonio Breast Cancer Symposium.

  2. 12-12-2022 | SABCS 2022 | Conference coverage | Article

    Phase 3 data support add-on capivasertib in people with AI-resistant advanced breast cancer

    “Capivasertib plus fulvestrant has the potential to be a future treatment option” for patients with hormone receptor-positive advanced breast cancer who have progressed on an endocrine-based regimen, concluded the investigator. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group SABCS 2022; San Antonio, Texas, USA: 6–10 December

    Author:
    Shreeya Nanda
    Published in:
    SABCS 2022; San Antonio, Texas, USA: 6–10 December
  3. 08-12-2022 | SABCS 2022 | Conference coverage | Article

    monarchE 4-year results show abemaciclib benefit is maintained beyond treatment completion

    These findings were simultaneously published in The Lancet Oncology . medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group SABCS 2022; San Antonio, Texas, USA: 6–10 December Lancet Oncol 2022; doi:10.1016/S1470-2045(22)00694-5

    Author:
    Shreeya Nanda
    Published in:
    SABCS 2022; San Antonio, Texas, USA: 6–10 December Lancet Oncol 2022; doi:10.1016/S1470-2045(22)00694-5
  4. 09-12-2022 | SABCS 2022 | Conference coverage | Article

    Encouraging data for neoadjuvant T-DXd in HER2-low early breast cancer

    The presenter concluded that “the study provides a rich platform for additional translational research to evaluate more sensitive methods of HER2 detection, develop predictive biomarkers, and understand mechanisms of resistance in residual disease which could guide subsequent therapeutic strategies, including combination therapy.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group SABCS 2022; San Antonio, Texas, USA: 6–10 December

    Author:
    Shreeya Nanda
    Published in:
    SABCS 2022; San Antonio, Texas, USA: 6–10 December
  5. 09-12-2022 | SABCS 2022 | Conference coverage | Article

    Next-generation oral SERD shows promise in ER-positive, advanced breast cancer

    In conclusion, Oliveira outlined the key next steps, including longer follow-up and analysis of overall survival as well as “detailed assessments of intersections and interactions between key subgroups” and “analysis of the rich translational dataset.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group SABCS 2022; San Antonio, Texas, USA: 6–10 December

    Author:
    Shreeya Nanda
    Published in:
    SABCS 2022; San Antonio, Texas, USA: 6–10 December
  6. 08-12-2022 | SABCS 2022 | Conference coverage | Article

    First-line ribociclib plus ET RIGHT Choice for aggressive advanced breast cancer

    The RIGHT Choice trial results suggest that “first-line ribociclib plus endocrine therapy can be an efficacious, clinically meaningful treatment option for patients with aggressive, advanced breast cancer, and help to avoid the need for combination chemotherapy and its associated toxicities,” concluded the presenter. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group SABCS 2022; San Antonio, Texas, USA: 6–10 December

    Author:
    Shreeya Nanda
    Published in:
    SABCS 2022; San Antonio, Texas, USA: 6–10 December
  7. 09-12-2021 | SABCS 2021 | Conference coverage | Article

    Novel SERD boosts PFS of patients with ER-positive, metastatic breast cancer

    He noted that “the final analysis with mature data is expected to take place in late 2022/early 2023.”

    Author:
    Shreeya Nanda
    Published in:
    SABCS 2021; 7–10 December
  8. 15-12-2020 | SABCS 2020 | Conference coverage | Article

    CONTESSA: Tesetaxel plus capecitabine boosts metastatic breast cancer PFS

    Overall survival data were not mature at the time of data cutoff, and the final analysis is expected in 2022, reported the presenter.

    Author:
    Shreeya Nanda
    Published in:
    SABCS 2020: 8–11 December
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.